Bristol Myers’ stock decline in response to weak guidance is a gift to investors

Health, Fitness & Food

Boxes of Opdivo from Bristol Myers are seen at the Huntsman Cancer Institute at the University of Utah in Salt Lake City, Utah, July 22, 2022.
George Frey | Reuters

Bristol Myers Squibb on Thursday reported better-than-expected quarterly results, but weak guidance for 2025 sent shares lower. Jim Cramer’s faith in the drugmaker is unshaken.

Products You May Like

Articles You May Like

Why Haven’t We Figured Out How to Protect Women Athletes?
Why nursing homes and hospice are so expensive in the U.S.
Free 7 Day Healthy Meal Plan (March 3-9)
Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
I Unlocked the Power of My Deepest Core Muscles, and I’ve Never Felt Stronger

Leave a Reply

Your email address will not be published. Required fields are marked *